The National Drug Early Warning System (NDEWS) Coordinating Center is pleased to announce the launch of the Drug Outbreak Testing Service (DOTS) pilot study. DOTS will support local experts and public health agencies experiencing a drug outbreak to identify the drug(s) behind the outbreak by providing free urinalyses of urine specimens already obtained from affected persons as part of standard treatment or administrative protocols.
Up to 20 de-identified urine specimens submitted to DOTS will be sent to an independent laboratory for testing for approximately 250 licit and illicit drugs, including synthetic opioids and other new psychoactive substances.
DEA: The Special Testing and Research Laboratory’s Emerging Trends Program compiled the data for this report through a query of archived seizure and analysis information from drug evidence analyzed by the Drug Enforcement Administration’s laboratory system. This data is representative of drug evidence seized and analyzed in the date ranges annotated. This is not a comprehensive list of all new psychoactive substances and is not representative of all evidence analyzed by DEA.
Understanding the geographic variations in impact on different population groups in the USA has become particularly necessary in light of the extreme increase in the use and misuse of street drugs including heroin and the subsequent rise in opioid-related deaths in the USA.
May 17, 2017: Treatment admissions data provide indicators of the health consequences of drug use and their impact on the treatment system (NIDA 2014). Eleven of the 12 NDEWS Sentinel Community Epidemiologists (SCEs) were able to provide the NDEWS Coordinating Center with 2015 treatment admissions data from their local sources; Atlanta Metro was the only site with no available data on 2015 treatment admissions. Note that the definition of the populations covered by each local treatment data source varies; however, the majority are based on admissions to programs receiving public funds.